Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Early Intervention, Randomized, Mulitcenter, Placebo-Controlled, 4-Period Crossover, Multi-Attack Study to Evaluate Efficacy & Safety of ComboProduct Containing Sumatriptan and Naproxen Sodium for Acute Treatment of Migraine in Adolescents

Next Previous
Search
Trial Profile

Early Intervention, Randomized, Mulitcenter, Placebo-Controlled, 4-Period Crossover, Multi-Attack Study to Evaluate Efficacy & Safety of ComboProduct Containing Sumatriptan and Naproxen Sodium for Acute Treatment of Migraine in Adolescents

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 22 Jun 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Naproxen sodium/sumatriptan (Primary)
  • Indications Migraine with aura; Migraine without aura
  • Focus Registrational; Therapeutic Use
  • Acronyms TEAM

    • Most Recent Events

    • 31 Mar 2016 The protocol has been amended with the cahnge in the primary endpoint timeframe from 2 years to 3 years.
    • 27 Oct 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 05 Mar 2013 Planned End Date changed from 1 Jan 2012 to 1 Jun 2013 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top